Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932087 | 1.00 | KMT2A (0.40) | KMT2AMEN1ACHECES2CES1 | |
| SCHEMBL6899887 | 0.91 | SMN1; SMN2 (0.47) | KMT2AMEN1ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL11932093 | 0.89 | MAPT (0.41) | KMT2AMEN1ACHECES2CES1 | |
| SCHEMBL16748974 | 0.89 | MAPT (0.41) | KMT2AMEN1ACHECES2CES1 | |
| SCHEMBL28016609 | 0.89 | MAPT (0.41) | KMT2AMEN1ACHECES2CES1 | |
| SCHEMBL1904465 | 0.88 | POLB (0.46) | KMT2AMEN1CES2CES1ALDH1A1 | |
| SCHEMBL9899896 | 0.88 | HDAC4 (0.42) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11932088 | 0.88 | POLB (0.46) | KMT2AMEN1CES2CES1ALDH1A1 | |
| SCHEMBL10347036 | 0.88 | ABCB11 (0.42) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL1904264 | 0.88 | HDAC4 (0.42) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012078674-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-20200385335-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20200385335-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20190185415-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185415-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-20180282262-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-10-04 | — | — | US | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2268625-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010102717-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102717-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | KMT2A 2766/4885MEN1 3585/4885ACHE 1477/4885 |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | KMT2A 4313/4885MEN1 3760/4885ACHE 3197/4885 |
| US-20190185415-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | KMT2A 4313/4885MEN1 3760/4885ACHE 3197/4885 |
| US-20200385335-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | KMT2A 4313/4885MEN1 3760/4885ACHE 3197/4885 |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | KMT2A 4313/4885MEN1 3760/4885ACHE 3197/4885 |
| US-20180282262-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | KMT2A 4313/4885MEN1 3760/4885ACHE 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.